drugset / Trial / NCT03630120
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
RandomizedParallel-groupSingle-blindTreatment
Summary
Participants will have been diagnosed with advanced progressive thyroid cancer and are about to start treatment with a tyrosine kinase inhibitor (TKI). The purpose of this study is to evaluate the efficacy and tolerability of tyrosine kinase inhibitor therapy (Lenvatinib or Sorafenib for differentiated thyroid cancer \[which includes papillary thyroid cancer, follicular thyroid cancer, and poorly differentiated thyroid cancer\]; and Cabozantinib or Vandetanib for medullary thyroid cancer) through adaptive (intermittent) versus conventional (continuous) regimen.
Timeline
- Start
- 2018-08-06
- Primary completion
- 2019-11-14
- Completion
- 2019-12-05
Outcome
Outcome not reported
Stopped: “Lack of efficacy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 140 mg | — |
| Subject | Lenvatinib | Small molecule | 24 mg | — |
| Subject | Sorafenib | Small molecule | 400 mg | — |
| Subject | Vandetanib | Small molecule | 300 mg | — |